REFERENCES
1. Infections in obstetrics: a guide for physicians. In: N.A. Korobkov, V.V. Vasil’ev, Yu.V. Lobzin, et al. Saint Petersburg: SpetsLit, 2019: 397 p. ISBN 978-5-299-00967-5. (in Russian)
2. Kholodnova N.V., Mazankova L.N., Vol’ter A.A.,Turina I.E. The modern view of congenital Сytomegalovirus infection. Detskie infektsii [Children’s Infections]. 2019; 18 (3): 46–52. DOI: https://doi.org/10.22627/2072-8107-2019-18-3-46-52 (in Russian)
3. Zaplatnikov A.L., Shakhgil’dyan V.I., Podzolkova N.M., et al. Is it possible to prevent the consequences of congenital cytomegalovirus infection? (the opinion of the obstetrician-gynecologist, neonatologist and infectiologist). RMZH. Meditsinskoe obozrenie [RMJ. Medical Review]. 2018; 2 (10): 45–50. (in Russian)
4. Hyde T.B., Schmid D.S., Cannon M.J. Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV. Rev Med Virol. 2010; 20 (5): 311–26.
5. Kenneson A., Cannon M.J. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007; 17 (4): 253–76.
6. Ornoy A., Diav-Citrin O. Fetal effects of primary and secondary cytomegalovirus infection in pregnancy. Reprod Toxicol. 2006; 21 (4): 399–409.
7. URL: https://cr.minzdrav.gov.ru/schema/288_1
8. URL: https://www.uptodate.com/contents/4810
9. Wang C., Zhang X., Bialek S., Cannon M.J. Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis. 2011; 52 (2): e11–3.
10. Davis N.L., King C.C., Kourtis A.P. Cytomegalovirus infection in pregnancy. Birth Defects Res. 2017; 109 (5): 336–46.
11. Chatzakis C., Ville Y., Makrydimas G., et al. Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences. Am J Obstet Gynecol. 2020; 223 (6): 870–83.
12. Revello M.G., Tibaldi C., Masuelli G., Frisina V., Sacchi A., Furione M., et al.; CCPE Study Group. Prevention of primary cytomegalovirus infection in pregnancy. EBioMedicine. 2015; 2 (9): 1205–10.
13. Kanengisser-Pines B., Hazan Y., Pines G., Appelman Z. High cytomegalovirus IgG avidity is a reliable indicator of past infection in patients with positive IgM detected during the first trimester of pregnancy. J Perinat Med. 2009; 37 (1): 15–8.
14. Gatta L.A., Rochat E., Weber J.M., et al. Clinical factors associated with cytomegalovirus shedding among seropositive pregnant women. Am J Obstet Gynecol MFM. 2022; 4 (2): 100560.
15. Tanimura K., Tairaku S., Morioka I., et al. Universal screening with use of immunoglobulin G avidity for congenital cytomegalovirus infection. Clin Infect Dis. 2017; 65: 1652–8.
16. Simonazzi G., Guerra B., Bonasoni P., et al. Fetal cerebral periventricular halo at midgestation: an ultrasound finding suggestive of fetal cytomegalovirus infection. Am J Obstet Gynecol. 2010; 202 (6): 599.e1–5.
17. Azam A.Z., Vial Y., Fawer C.L., et al. Prenatal diagnosis of congenital cytomegalovirus infection. Obstet Gynecol. 2001; 97 (3): 443–8.
18. Liesnard C., Donner C., Brancart F., et al. Prenatal diagnosis of congenital cytomegalovirus infection: prospective study of 237 pregnancies at risk. Obstet Gynecol. 2000; 95 (5): 881–8.
19. Buca D., Di Mascio D., Rizzo G., et al. Outcome of fetuses with congenital cytomegalovirus infection and normal ultrasound at diagnosis: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2021; 57 (4): 551–9.
20. Vauloup-Fellous C., Picone O., Cordier A.G., et al. Does hygiene counseling have an impact on the rate of CMV primary infection during pregnancy? Results of a 3-year prospective study in a French hospital. J Clin Virol. 2009; 46 (suppl 4): S49–53.
21. Adler S.P., Finney J.W., Manganello A.M., Best A.M. Prevention of child-to-mother transmission of cytomegalovirus among pregnant women. J Pediatr. 2004; 145 (4): 485–91.
22. Kagan K.O., Enders M., Schampera M.S., Baeumel E., Hoopmann M., Geipel A., et al. Prevention of maternal-fetal transmission of cytomegalovirus after primary maternal infection in the first trimester by biweekly hyperimmunoglobulin administration. Ultrasound Obstet Gynecol. 2019; 53 (3): 383–9. DOI: https://doi.org/10.1002/uog.19164
23. Devlieger R., Buxmann H., Nigro G., Enders M., Jückstock J., Siklós P., et al. Serial monitoring and hyperimmunoglobulin versus standard of care to prevent congenital cytomegalovirus infection: a phase III randomized trial. Fetal Diagn Ther. 2021; 48 (8): 611–23. DOI: https://doi.org/10.1159/000518508
24. Revello M.G., Lazzarotto T., Guerra B., Spinillo A., Ferrazzi E., Kustermann A., et al.; CHIP Study Group. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med. 2014; 370 (14): 1316–26. DOI: https://doi.org/10.1056/NEJMoa1310214
25. Hughes B.L., Clifton R.G., Rouse D.J., Saade G.R., Dinsmoor M.J., Reddy U.M., et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. A trial of hyperimmune globulin to prevent congenital cytomegalovirus infection. N Engl J Med. 2021; 385 (5): 436–44. DOI: https://doi.org/10.1056/NEJMoa1913569
26. URL: https://www.drugs.com/pregnancy/valacyclovir.html
27. D’Antonio F., Marinceu D., Prasad S., Khalil A. Effectiveness and safety of prenatal valacyclovir for congenital cytomegalovirus infection: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2023; 61 (4): 436–44. DOI: https://doi.org/10.1002/uog.26136